Level C· Early human research exploring benefitsRetrospective StudyEurope PMCOpen access

Pathological classification of chronic radiation-induced intestinal injury and its clinical implications

Wang YT., Zhu YX., Huang RY., Huang Y., Wan XB., Huang XY.

Retrospective Study with a reported sample of 111 on Autoimmune Research, published in Gastroenterol Rep (Oxf) (2025) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Retrospective Study
Journal
Gastroenterol Rep (Oxf) (2025)
Reported sample size
111
Source database
Europe PMC
PMID
40656550
PMCID
PMC12255887
DOI
10.1093/gastro/goaf072
Citations
2

Abstract (original English)

Background Chronic radiation-induced intestinal injury (CRIII) is the most prevalent condition following radiation therapy in patients with pelvic malignancies. More than 15% of patients with severe CRIII require surgery. The histopathological features and their interactions with clinical presentation and outcomes remain largely unknown. The present study proposed a new pathological categorization of CRIII and investigated its relationship with clinical manifestations and outcomes. Methods This retrospective study included 111 patients with CRIII who were treated at the Sixth Affiliated Hospital of Sun Yat-sen University (Guangzhou, China) between January 2011 and December 2021. The features of ulcers, collagen fibers, and neoangiogenesis were measured via microscopic scoring, Masson's trichrome staining, and immunohistochemistry for CD34. The K-means method was used for cluster analysis based on these three data groups. The Kaplan-Meier method and log-rank test were used to examine the incidence-time curves of severe complications, including intestinal fistula, intestinal obstruction, and anemia, as endpoint events. Cox proportional hazards regression models were used for multivariate analyses. Results Four pathological CRIII subtypes were identified: mixed (48.7%), fibrosis (17.1%), telangiectasia (16.2%), and ulcers (18.0%). Patients with the ulcer subtype had a significant

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • Without an adequate control group, treatment effects cannot be separated from other factors.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research